Compare TransMedics Group Inc (TMDX) vs Warner Music Group Corp (WMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Warner Music Group Corp — how do they compare? TransMedics Group Inc trades at $85.89 (market cap $3.06B), while Warner Music Group Corp trades at $28.16 (market cap $14.66B). The key difference: Warner Music Group Corp is far larger — about 4.8× TransMedics Group Inc's market cap, and Warner Music Group Corp pays a 2.85% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| TMDX | WMG | |
|---|---|---|
Market Cap | $3.06B | $14.66B |
Sector | Technology | Media |
52-Week High | $150.42 | $34.72 |
52-Week Low | $61.99 | $23.65 |
Enterprise Value | $3.46B | $18.96B |
Dividend Yield | — | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Warner Music Group (WMG) trades at $28.03, down 2.61% on the day, with a bearish technical signal. Recent earnings show mixed quarterly beats, with Q1 and Q2 2026 exceeding expectations but Q4 2025 missing. Revenue has grown steadily from $5.9B in 2022 to $6.7B in 2025, though net income margin declined to 5.44%. The company maintains a strong ROE of 25.38% and recently announced a strategic AI music partnership with Suno (Reuters, 2026-09-09).
Outlook is cautiously optimistic with analyst consensus at 66.7% buy ratings. Key opportunities include streaming growth and AI initiatives, while risks involve margin pressure and leadership changes. The stock's valuation at a P/E of 22.42 appears reasonable given growth prospects, but investors should monitor execution on margin improvement and competitive dynamics in the music industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
